|
1
|
Osborne CK, Shou J, Massarweh S and Schiff
R: Crosstalk between estrogen receptor and growth factor receptor
pathways as a cause for endocrine therapy resistance in breast
cancer. Clin Cancer Res. 11:865s–870s. 2005.PubMed/NCBI
|
|
2
|
Parton M, Dowsett M and Smith I: Studies
of apoptosis in breast cancer. BMJ. 322:1528–1532. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hanstein B, Djahansouzi S, Dall P,
Beckmann MW and Bender HG: Insights into the molecular biology of
the estrogen receptor define novel therapeutic targets for breast
cancer. Eur J Endocrinol. 150:243–255. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yarden Y: Biology of HER2 and its
importance in breast cancer. Oncology. 61(Suppl 2): 1–13. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yamamoto T, Ikawa S, Akiyama T, Semba K,
Nomura N, Miyajima N, Saito T and Toyoshima K: Similarity of
protein encoded by the human c-erb-B-2 gene to epidermal growth
factor receptor. Nature. 319:230–234. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hynes NE and Stern DF: The biology of
erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta.
1198:165–184. 1994.PubMed/NCBI
|
|
7
|
Arpino G, Wiechmann L, Osborne CK and
Schiff R: Crosstalk between the estrogen receptor and the HER
tyrosine kinase receptor family: Molecular mechanism and clinical
implications for endocrine therapy resistance. Endocr Rev.
29:217–233. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baselga J: Treatment of
HER2-overexpressing breast cancer. Ann Oncol. 21(Suppl 7):
vii36–vii40. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim KC, Kim JS, Son JK and Kim IG:
Enhanced induction of mitochondrial damage and apoptosis in human
leukemia HL-60 cells by the Ganoderma lucidum and Duchesnea
chrysantha extracts. Cancer Lett. 246:210–217. 2007. View Article : Google Scholar
|
|
10
|
Mow BM, Blajeski AL, Chandra J and
Kaufmann SH: Apoptosis and the response to anticancer therapy. Curr
Opin Oncol. 13:453–462. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim R: Recent advances in understanding
the cell death pathways activated by anticancer therapy. Cancer.
103:1551–1560. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mellier G, Huang S, Shenoy K and Pervaiz
S: TRAILing death in cancer. Mol Aspects Med. 31:93–112. 2010.
View Article : Google Scholar
|
|
13
|
Chipuk JE, Moldoveanu T, Llambi F, Parsons
MJ and Green DR: The BCL-2 family reunion. Mol Cell. 37:299–310.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li D, Qu X, Hou K, Zhang Y, Dong Q, Teng
Y, Zhang J and Liu Y: PI3K/Akt is involved in bufalin-induced
apoptosis in gastric cancer cells. Anticancer Drugs. 20:59–64.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Takeuchi H, Kim J, Fujimoto A, Umetani N,
Mori T, Bilchik A, Turner R, Tran A, Kuo C and Hoon DS: X-Linked
inhibitor of apoptosis protein expression level in colorectal
cancer is regulated by hepatocyte growth factor/C-met pathway via
Akt signaling. Clin Cancer Res. 11:7621–7628. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee SM, Lee CT, Kim YW, Han SK, Shim YS
and Yoo CG: Hypoxia confers protection against apoptosis via
PI3K/Akt and ERK pathways in lung cancer cells. Cancer Lett.
242:231–238. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bak Y, Kim H, Kang JW, Lee DH, Kim MS,
Park YS, Kim JH, Jung KY, Lim Y, Hong J, et al: A synthetic
naringenin derivative, 5-hydroxy-7,4′-diacetyloxyflavanone-N-phenyl
hydrazone (N101-43), induces apoptosis through up-regulation of
Fas/ FasL expression and inhibition of PI3K/Akt signaling pathways
in non-small-cell lung cancer cells. J Agric Food Chem.
59:10286–10297. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xia Z, Dickens M, Raingeaud J, Davis RJ
and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases
on apoptosis. Science. 270:1326–1331. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sebolt-Leopold JS: Development of
anticancer drugs targeting the MAP kinase pathway. Oncogene.
19:6594–6599. 2000. View Article : Google Scholar
|
|
20
|
Hilger RA, Scheulen ME and Strumberg D:
The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie.
25:511–518. 2002. View Article : Google Scholar
|
|
21
|
Yager JD and Davidson NE: Estrogen
carcinogenesis in breast cancer. N Engl J Med. 354:270–282. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
de Leeuw R, Neefjes J and Michalides R: A
role for estrogen receptor phosphorylation in the resistance to
tamoxifen. Int J Breast Cancer. 2011:2324352011. View Article : Google Scholar
|
|
23
|
Thomas RS, Sarwar N, Phoenix F, Coombes RC
and Ali S: Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is
important for estrogen receptor-alpha activity. J Mol Endocrinol.
40:173–184. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Weitsman GE, Li L, Skliris GP, Davie JR,
Ung K, Niu Y, Curtis-Snell L, Tomes L, Watson PH and Murphy LC:
Estrogen receptor-alpha phosphorylated at Ser118 is present at the
promoters of estrogen-regulated genes and is not altered due to
HER-2 overexpression. Cancer Res. 66:10162–10170. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bhatt S, Xiao Z, Meng Z and
Katzenellenbogen BS: Phosphorylation by p38 mitogen-activated
protein kinase promotes estrogen receptor α turnover and functional
activity via the SCF(Skp2) proteasomal complex. Mol Cell Biol.
32:1928–1943. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Marino M, Acconcia F, Bresciani F, Weisz A
and Trentalance A and Trentalance A: Distinct nongenomic signal
transduction pathways controlled by 17beta-estradiol regulate DNA
synthesis and cyclin D(1) gene transcription in HepG2 cells. Mol
Biol Cell. 13:3720–3729. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Marino M, Acconcia F and Trentalance A:
Biphasic estradiol-induced AKT phosphorylation is modulated by PTEN
via MAP kinase in HepG2 cells. Mol Biol Cell. 14:2583–2591. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gutierrez-Orozco F and Failla ML:
Biological activities and bioavailability of mangosteen xanthones:
A critical review of the current evidence. Nutrients. 5:3163–3183.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sakagami Y, Iinuma M, Piyasena KG and
Dharmaratne HR: Antibacterial activity of alpha-mangostin against
vancomycin resistant Enterococci (VRE) and synergism with
antibiotics. Phytomedicine. 12:203–208. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gopalakrishnan G, Banumathi B and Suresh
G: Evaluation of the antifungal activity of natural xanthones from
Garcinia mangostana and their synthetic derivatives. J Nat Prod.
60:519–524. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sidahmed HM, Abdelwahab SI, Mohan S,
Abdulla MA, Taha MME, Hashim NM, Hadi AHA, Vadivelu J, Fai ML,
Rahmani M, et al: alpha-Mangostin from Cratoxylum arborescens
(Vahl) blume demonstrates anti-ulcerogenic property: A mechanistic
study. Evid Based Complement Alternat Med. 2013:4508402013.
View Article : Google Scholar
|
|
32
|
Huang HJ, Chen WL, Hsieh RH and Hsieh-Li
HM: Multifunctional effects of mangosteen pericarp on cognition in
C57BL/6J and triple transgenic Alzheimer's mice. Evid Based
Complement Alternat Med. 2014:8136722014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pedraza-Chaverrí J, Reyes-Fermín LM,
Nolasco-Amaya EG, Orozco-Ibarra M, Medina-Campos ON,
González-Cuahutencos O, Rivero-Cruz I and Mata R: ROS scavenging
capacity and neuroprotective effect of alpha-mangostin against
3-nitropropionic acid in cerebellar granule neurons. Exp Toxicol
Pathol. 61:491–501. 2009. View Article : Google Scholar
|
|
34
|
Pedraza-Chaverri J, Cárdenas-Rodríguez N,
Orozco-Ibarra M and Pérez-Rojas JM: Medicinal properties of
mangosteen (Garcinia mangostana). Food Chem Toxicol. 46:3227–3239.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Devi Sampath P and Vijayaraghavan K:
Cardioprotective effect of alpha-mangostin, a xanthone derivative
from mangosteen on tissue defense system against
isoproterenol-induced myocardial infarction in rats. J Biochem Mol
Toxicol. 21:336–339. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Suksamrarn S, Suwannapoch N, Phakhodee W,
Thanuhiranlert J, Ratananukul P, Chimnoi N and Suksamrarn A:
Antimycobacterial activity of prenylated xanthones from the fruits
of Garcinia mangostana. Chem Pharm Bull (Tokyo). 51:857–859. 2003.
View Article : Google Scholar
|
|
37
|
Nguyen PT and Marquis RE: Antimicrobial
actions of α-mangostin against oral streptococci. Can J Microbiol.
57:217–225. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kaomongkolgit R, Jamdee K and Chaisomboon
N: Antifungal activity of alpha-mangostin against Candida albicans.
J Oral Sci. 51:401–406. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen LG, Yang LL and Wang CC:
Anti-inflammatory activity of mangostins from Garcinia mangostana.
Food Chem Toxicol. 46:688–693. 2008. View Article : Google Scholar
|
|
40
|
Chairungsrilerd N, Furukawa K, Ohta T,
Nozoe S and Ohizumi Y: Pharmacological properties of
alpha-mangostin, a novel histamine H1 receptor antagonist. Eur J
Pharmacol. 314:351–356. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sánchez-Pérez Y, Morales-Bárcenas R,
García-Cuellar CM, López-Marure R, Calderon-Oliver M,
Pedraza-Chaverri J and Chirino YI: The alpha-mangostin prevention
on cisplatin-induced apoptotic death in LLC-PK1 cells is associated
to an inhibition of ROS production and p53 induction. Chem Biol
Interact. 188:144–150. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nabandith V, Suzui M, Morioka T, Kaneshiro
T, Kinjo T, Matsumoto K, Akao Y, Iinuma M and Yoshimi N: Inhibitory
effects of crude alpha-mangostin, a xanthone derivative, on two
different categories of colon preneoplastic lesions induced by 1,
2-dimethylhydrazine in the rat. Asian Pac J Cancer Prev. 5:433–438.
2004.PubMed/NCBI
|
|
43
|
Nakagawa Y, Iinuma M, Naoe T, Nozawa Y and
Akao Y: Characterized mechanism of alpha-mangostin-induced cell
death: Caspase-independent apoptosis with release of endonuclease-G
from mitochondria and increased miR-143 expression in human
colorectal cancer DLD-1 cells. Bioorg Med Chem. 15:5620–5628. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Matsumoto K, Akao Y, Yi H, Ohguchi K, Ito
T, Tanaka T, Kobayashi E, Iinuma M and Nozawa Y: Preferential
target is mitochondria in alpha-mangostin-induced apoptosis in
human leukemia HL60 cells. Bioorg Med Chem. 12:5799–5806. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Krajarng A, Nakamura Y, Suksamrarn S and
Watanapokasin R: α-Mangostin induces apoptosis in human
chondrosarcoma cells through downregulation of ERK/JNK and Akt
signaling pathway. J Agric Food Chem. 59:5746–5754. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tewtrakul S, Wattanapiromsakul C and
Mahabusarakam W: Effects of compounds from Garcinia mangostana on
inflammatory mediators in RAW264.7 macrophage cells. J
Ethnopharmacol. 121:379–382. 2009. View Article : Google Scholar
|
|
47
|
Sebastian KS and Thampan RV: Differential
effects of soybean and fenugreek extracts on the growth of MCF-7
cells. Chem Biol Interact. 170:135–143. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sethi G, Sung B and Aggarwal BB: Nuclear
factor-kappaB activation: From bench to bedside. Exp Biol Med
(Maywood). 233:21–31. 2008. View Article : Google Scholar
|
|
49
|
Tabas I and Ron D: Integrating the
mechanisms of apoptosis induced by endoplasmic reticulum stress.
Nat Cell Biol. 13:184–190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Dhanasekaran DN and Reddy EP: JNK
signaling in apoptosis. Oncogene. 27:6245–6251. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Li J and Holbrook NJ: Elevated
gadd153/chop expression and enhanced c-Jun N-terminal protein
kinase activation sensitizes aged cells to ER stress. Exp Gerontol.
39:735–744. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Tiwary R, Yu W, Li J, Park SK, Sanders BG
and Kline K: Role of endoplasmic reticulum stress in alpha-TEA
mediated TRAIL/ DR5 death receptor dependent apoptosis. PLoS One.
5:e118652010. View Article : Google Scholar
|
|
53
|
Ménard S, Tagliabue E, Campiglio M and
Pupa SM: Role of HER2 gene overexpression in breast carcinoma. J
Cell Physiol. 182:150–162. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Clark AS, West K, Streicher S and Dennis
PA: Constitutive and inducible Akt activity promotes resistance to
chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol
Cancer Ther. 1:707–717. 2002.PubMed/NCBI
|
|
55
|
Brognard J, Clark AS, Ni Y and Dennis PA:
Akt/protein kinase B is constitutively active in non-small cell
lung cancer cells and promotes cellular survival and resistance to
chemotherapy and radiation. Cancer Res. 61:3986–3997.
2001.PubMed/NCBI
|
